This showed a significant reduction of the ejection fraction by 30% (P=0.007; Fig. 1G).
All animals displayed the typical alterations of HF, including significant reduction of LV ejection fraction (LVEF) compared to healthy animals and increase of LV end-diastolic pressure (LVEDP), which reached 20 ± 6 mmHg after 21 ± 2 days of pacing.
The hearts of MLP-KO and β-catenin c∆ex3 mice showed a significant reduction of the ejection fraction (EF) already at the age of 5 weeks which was even more pronounced at a higher age (Fig. 2b), demonstrating a continuous deterioration of cardiac function during disease progression.
Six patients had an asymptomatic reduction of left ventricular ejection fraction of ≥20% versus baseline.
The starch tablets were observed to undergo 'recompression' or height reduction in the early stages of ejection, followed by height expansion as they moved further towards the die exit and during emergence.
Acid aspiration led to increased CVP and mPAP with a significant reduction of the right ventricular ejection fraction, while MAP and CO remained constant.
In all, 10 patients (17.2%) had a major cardiac abnormality: five had evidence of mixed aortic abnormality; three had mitral regurgitation, one had a mitral/aortic valve replacement; and five had a reduction in ejection fraction of less than 50% (Table 2).
The progression of symptomatic HF was associated with the reduction of the left ventricle (LV) ejection fraction in both sexes (all p < 0.05).
One further patient suffered a cardiac DLT after a single dose of 125 mg m−2, with a reduction in Ejection Fraction (EF) by more than 20%74to54o 54%).
Initially systolic and diastolic volumes were enlarged in AAB groups at 4 weeks post induction of hypertrophy, which resulted in a reduction in ejection fraction.
